Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Elzonris (tagraxofusp-erzs) is indicated for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and pediatric patients 2 years and older.
• This summary is based on the review of two systematic review(s)/meta-analysis(es). ^[1-2]
• Tagraxofusp (Elzonris) demonstrates effectiveness in treating both newly diagnosed and relapsed/refractory BPDCN patients, including facilitating successful bridging to hematopoietic stem cell transplantation (HSCT).
• High rates of effectiveness are observed in adult populations, including treatment-naïve and previously treated patients, with a more limited but still effective experience in pediatric patients.
• There is a notable difference in the extent of data available between adult and pediatric populations, with more extensive data supporting the effectiveness in adults.
• Tagraxofusp is generally safe for use in both treatment-naïve and previously treated adult patients, and it also demonstrates safety in pediatric patients aged 2 years and older, though with more limited experience.
• The most significant safety concern identified is the risk of potentially fatal capillary leak syndrome, necessitating careful patient selection and monitoring.